The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Glaucoma and ocular hypertension happen when fluid builds up inside the eye, raising internal pressure. Over time, high pressure can damage the optic nerve and harm your eyesight. The standard treatment is usually daily eye drops, but many people find it difficult to remember to use them every single day. This Phase 3 trial tests a new approach called Bimatoprost SR. It is a tiny, dissolvable implant placed directly into the front of the eye by an eye specialist. It is designed to release pressure-lowering medicine slowly over several months. The trial compares this implant to standard daily eye drops called timolol. Researchers will measure eye pressure at different hours of the day to see if the implant works as well as, or better than, regular drops at keeping eye pressure at a safe level.
At a glance
What is this study about?
Glaucoma is a common eye condition where the optic nerve, which connects the eye to the brain, becomes damaged. In most cases, this happens because fluid cannot drain properly from the eye, causing pressure to build up. This increased pressure is known as ocular hypertension. If left untreated, high eye pressure can gradually steal your sight, often starting with your side vision.
At the moment, most people manage eye pressure with prescription eye drops taken once or twice a day. While drops work well, using them every day for life can be challenging. Many people forget doses, struggle to put drops in, or experience side effects like stinging and dry eyes. When doses are missed, eye pressure can rise again without the person noticing.
This clinical trial is testing an alternative called Bimatoprost SR. Instead of daily drops, a doctor places a microscopic implant inside the front of the eye. The implant slowly dissolves on its own, steadily releasing medicine over months. In this trial, researchers want to see if the implant is safe and effective compared to standard timolol eye drops.
Because this is a Phase 3 study, it involves a large group of people to confirm whether the treatment is reliable enough to be approved for wider medical use. If successful, this slow-release treatment could offer people with glaucoma a way to protect their vision without having to worry about daily drops.
Key takeaways
- Tests a dissolving eye implant designed to lower pressure without daily drops.
- Open to adults aged 18 and older with open-angle glaucoma or ocular hypertension.
- Compares the implant against standard timolol drops over several months.
- The implant is placed in the eye by a doctor after numbing drops are applied.
- Joining is completely voluntary and you can withdraw at any time.
Who may be eligible?
This trial is open to adults aged 18 and over who have been diagnosed with open-angle glaucoma or ocular hypertension in one or both eyes. Both men and women can take part.
To join, your eye pressure must fall within a specific range suitable for the study. You will also need to be able to attend regular clinic appointments for detailed eye tests and follow-up checks.
You may not be able to take part if you have certain other eye conditions, advanced sight loss, previous complex eye surgeries, or allergies to the study medications. An eye doctor at the study centre will carefully examine your eyes to make sure taking part is safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with open-angle glaucoma or ocular hypertension.
- I am looking for an alternative to managing daily eye drops.
- I am able to attend regular daytime clinic appointments for eye checks.
- I do not have severe, untreated eye infections or complex eye conditions.
What does participation involve?
Taking part begins with a screening visit where doctors check your overall health and thoroughly examine your eyes. If you are eligible, you will be randomly placed into a treatment group. You may receive the Bimatoprost SR implant, standard timolol eye drops, or a harmless dummy (placebo) version to ensure the test results are completely fair. The implant is placed during a quick, simple procedure in the clinic after your eye has been completely numbed with drops. Over the course of the study, you will attend regular follow-up visits so doctors can check your eye health and measure your pressure at specific times of the day. The study usually lasts several months to monitor how long the treatment lasts and how well your eyes tolerate it.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is the Bimatoprost SR implant?
It is an extremely tiny pellet, smaller than a grain of rice, that is placed in the eye. It slowly dissolves and releases pressure-lowering medicine over time.
Will having the implant put in hurt?
Before the procedure, the eye doctor will use numbing drops so you do not feel pain. You may feel a slight pressure, but it is typically quick and straightforward.
Can I choose whether I get the implant or eye drops?
No. A computer randomly decides which group you join. This is standard in clinical trials to ensure the results are unbiased and scientifically sound.
Do I have to pay for the treatment?
No. All study medications, eye examinations, and trial-related care are provided free of charge.
What happens if I change my mind?
You are free to leave the trial at any point. Deciding to withdraw will never affect your regular NHS eye care or your relationship with your doctors.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.